###begin article-title 0
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ex Vivo</italic>
###xml 110 115 <span type="species:ncbi:10090">Mouse</span>
In Vivo and Ex Vivo Evaluation of L-Type Calcium Channel Blockers on Acid beta-Glucosidase in Gaucher Disease Mouse Models
###end article-title 0
###begin p 1
Conceived and designed the experiments: YS YHX GG. Performed the experiments: BL BQ HR. Analyzed the data: YS BL BQ HR YHX GG. Wrote the paper: YS GG.
###end p 1
###begin p 2
###xml 693 700 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1151 1158 1148 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1291 1298 1288 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 1215 1220 <span type="species:ncbi:10090">mouse</span>
Gaucher disease is a lysosomal storage disease caused by mutations in acid beta-glucosidase (GCase) leading to defective hydrolysis and accumulation of its substrates. Two L-type calcium channel (LTCC) blockers-verapamil and diltiazem-have been reported to modulate endoplasmic reticulum (ER) folding, trafficking, and activity of GCase in human Gaucher disease fibroblasts. Similarly, these LTCC blockers were tested with cultured skin fibroblasts from homozygous point-mutated GCase mice (V394L, D409H, D409V, and N370S) with the effect of enhancing of GCase activity. Correspondingly, diltiazem increased GCase protein and facilitated GCase trafficking to the lysosomes of these cells. The in vivo effects of diltiazem on GCase were evaluated in mice homozygous wild-type (WT), V394L and D409H. In D409H homozygotes diltiazem (10 mg/kg/d via drinking water or 50-200 mg/kg/d intraperitoneally) had minor effects on increasing GCase activity in brain and liver (1.2-fold). Diltiazem treatment (10 mg/kg/d) had essentially no effect on WT and V394L GCase protein or activity levels (<1.2-fold) in liver. These results show that LTCC blockers had the ex vivo effects of increasing GCase activity and protein in the mouse fibroblasts, but these effects did not translate into similar changes in vivo even at very high drug doses.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 178 181 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Beutler1">[1]</xref>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 375 378 375 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 441 444 441 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Beutler1">[1]</xref>
###xml 582 585 582 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 771 774 771 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 776 779 776 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Tsuji1">[3]</xref>
###xml 781 784 781 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Charrow1">[4]</xref>
###xml 941 944 941 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 1077 1080 1077 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Eyal1">[5]</xref>
###xml 1162 1165 1162 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-PasmanikChor1">[6]</xref>
###xml 1327 1330 1327 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Theophilus1">[7]</xref>
###xml 1422 1425 1422 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 1502 1505 1502 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 1570 1573 1570 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
###xml 1187 1193 <span type="species:ncbi:9606">humans</span>
###xml 1347 1353 <span type="species:ncbi:9606">humans</span>
###xml 1387 1391 <span type="species:ncbi:10090">mice</span>
###xml 1430 1434 <span type="species:ncbi:10090">mice</span>
Deficiency of GCase leads to accumulation of its substrates, glucosylceramide (GC) and glucosylsphingosine (GS), and the resultant visceral and CNS phenotypes in Gaucher disease [1], [2]. Three types of Gaucher disease are clinically delineated, based on age at recognition and organ involvement. Type 1 is the non-neuronopathic variant with highly variable visceral disease [2]. Types 2 and 3 have early onset of variable CNS deterioration [1]. About 350 mutations in GCase have been identified in DNAs from affected patients and many of these are rare or occur in single families [2]. A mutation with high frequency in the Ashkenazi Jewish population is N370S. Homozygosity for N370S is associated with type 1, non-neuropathic disease and variable visceral involvement [2], [3], [4]. The L444P recurrent mutation is highly associated with neuronopathic variants of Gaucher disease, and is the most common Gaucher disease allele world-wide [2]. The D409H alleles also has significant frequency and homozygotes manifest early onset of variable visceral and the CNS involvement [5]. Uniquely, calcific aortic root and valve disease occurs with D409H homozygosity [6]. The V394L allele in humans has been reported only in the heteroallele state and is associated with either type 1 or types 2 and 3 depending on the heteroallele [7]. In contrast to humans, N370S and L444P homozygosity in mice lead to death within 24 hours [8]. In mice homozygosity for V394L and D409H leads to defective GCase activity [8] and survival to >12 mos. with only minor visceral abnormalities [8].
###end p 4
###begin p 5
###xml 217 220 217 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Weinreb1">[9]</xref>
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Weinreb2">[10]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Butters1">[11]</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
Currently treatment for Gaucher disease includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). ERT has significantly improved the health of Gaucher patients by reversing the visceral disease [9], but it has no effect on the neuronopathic manifestations due to the insufficient amounts of enzyme penetrating the blood-brain barrier (BBB) for therapeutic effect. SRT has been used with patients who cannot receive ERT, but the therapeutic index of SRT is low, and it is associated with more side effects [10]. The FDA and EMEA approved drug for SRT, miglustat, does penetrate the blood brain barrier [11]. Both ERT and SRT are expensive: >50% shaded block130,000-300,000 per year for drug costs alone. Alternative therapies are needed to access the CNS and reduce the costs.
###end p 5
###begin p 6
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Lieberman1">[13]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Lieberman1">[13]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Rigat1">[14]</xref>
###xml 632 639 632 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 644 651 644 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
Small molecules that modulate in vivo or ex vivo GCase stability or activity have been evaluated recently [12], [13]. For selected GCase variants, a so-called pharmacological chaperone, isofagomine (IFG), enhances GCase activity by stabilizing the enzyme in the ER or enhancing transport of mature GCases into the lysosome or both [13]. Two LTCC blockers, verapamil and diltiazem, were reported to affect ER folding, trafficking, and activity of GCase in fibroblasts from Gaucher disease patients [12], [14]. Here, these LTCC blockers were evaluated in GCase point mutated mice and derived cells for their effects on GCase activity in vivo and ex vivo.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 520 527 510 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g001">Fig. 1A</xref>
###xml 865 872 807 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g001">Fig. 1C</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Mouse fibroblasts were from WT, GCase point-mutated mice (V394L, D409H, and N370S homozygotes, D409V/N370S compound heterozygotes), and saposin C-deficient (C-/-) plus V394L homozygotes (4L;C*). These cells were grown to 35% confluency and incubated in a medium containing diltiazem (0 to 50 microM) for 5 days. The cell lysates were assayed for GCase activity and protein. GCase activity in V394L, D409H, N370S, C-/-, and 4L;C* fibroblasts increased >/=1.5-fold at 50 microM diltiazem in the dose-response experiments (Fig. 1A). The maximal GCase enhancements with V394L was achieved at approximately6 microM and with 4L;C* at approximately12 microM. WT and D409V/N370S fibroblasts showed a approximately1.3-fold increase in GCase activity at 50 microM. These maximal activities for each of the cell strains are displayed as the percentage of untreated WT levels (Fig. 1C). Relative to untreated WT, diltiazem-treated mutant cells achieved 13% to 35% of the WT GCase activity levels. The activities were significantly increased by 1.3- to 2.6-fold compared to untreated cells. Only diltiazem-treated C-/- cells achieved WT GCase activity levels.
###end p 8
###begin title 9
Diltiazem (A) and Verapamil (B) effects on GCase activities in fibroblasts.
###end title 9
###begin p 10
(A) Fold increase in GCase activities in diltiazem treated fibroblasts from WT (*), D409H homozygote (9H; square), V394L homozygote (4L; Delta), N370S homozygote (OS; black triangle down), 4L;C* V394L plus C-/- (4L;C*; o), (saposin C-/-) (C-/-; lozenge) and D409V/N370S compound heterozygote (9V/OS; blacksquare, square, filled). (B) Fold increase in GCase activities in verapamil treated fibroblasts from WT, 9H, 4L, OS, 4L;C*, C-/- and 9V/OS compound heterozygotes. The cells were incubated in the presence of diltiazem or verapamil for 5 days. The enhancements of specific GCase activities in treated cells are presented as fold increase relative to the respective untreated cells. (C) Percentage of untreated WT activity in diltiazem (0 or 50 microM) treated fibroblasts. The GCase activities were significantly increased in treated fibroblasts. The activities in all treated GCase mutant cells (9H, 4L, OS, 4L;C* and 9V/OS) were below 35% of WT levels. Fold-changes (mean +/- S.E.M) of diltiazem effects on GCase for each cell line are above the columns. The experiments were done in triplicates. Student's t test, ***, p<0.001.
###end p 10
###begin p 11
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g001">Fig. 1B</xref>
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
###xml 438 443 <span type="species:ncbi:10090">mouse</span>
A second LTCC blocker, verapamil, was tested for its effects on GCase activities from the same mouse fibroblasts (Fig. 1B). The GCase activities in verapamil-treated V394L and N370S cells showed a >/=1.5-fold activation at 25 microM. WT cells responded to verapamil with approximately1.3-fold enhancement of activity. The other cells had a </=1.3-fold increase in GCase activity. These results indicate that both WT and variant GCases in mouse fibroblasts responded to diltiazem and verapamil. Diltiazem had more significant effects on GCase than verapamil. The enhanced activities from those treated GCase mutant were >/=35% of the WT level.
###end p 11
###begin p 12
###xml 364 370 364 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g002">Fig. 2</xref>
###xml 658 664 654 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g003">Fig. 3</xref>
###xml 989 993 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Zinchuk1">[15]</xref>
###xml 1382 1388 1378 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g003">Fig. 3</xref>
###xml 1390 1397 1386 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007320-t001">Table 1</xref>
###xml 191 197 <span type="species:ncbi:9986">rabbit</span>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
###xml 481 485 <span type="species:ncbi:9925">goat</span>
###xml 491 496 <span type="species:ncbi:10090">mouse</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
GCase protein levels and lysosomal localization were determined in diltiazem-treated V394L, D409H, 4L;C*, C-/-, and WT cells. GCase protein levels were assessed by immuno blot analysis using rabbit anti-mouse GCase antibody. Compared to untreated cells, GCase protein levels were significantly increased by 1.3- to 1.7-fold in the treated cells with any genotype (Fig. 2). GCase trafficking to the lysosome was analyzed by colocalization quantification of fluorescent signals from goat anti-mouse GCase (FITC, green) and lysosome marker (LysoTracker or Lamp1, Red). Diltiazem (25 microM) enhanced GCase signals in cells from WT, V394L, C-/-, and 4L;C* mice (Fig. 3). Pearson's correlation coefficients were used to determine the degree of colocalization of the GCase signals with lysosomal signals (LysoTrack or Lamp1) and their change with diltizem treatment. These coefficients portray the degree of overlap between two images in FITC and Rhodamine channels and not the level of signals [15], i.e., values of 0 and 1 indicate no correlation and complete correlation, respectively. Diltiazem treatment significantly increased Pearson's correlation coefficients for GCase in WT, C-/-, D409H, V394L, and 4L;C* cells. The GCases prior to treatment were localized mostly to the perinuclear regions, whereas following treatment there were much greater lysosomal colocalization signals (Fig. 3, Table 1). These results indicate that diltiazem increases the GCase protein levels and facilitates GCase trafficking into lysosomes in cultured fibroblasts.
###end p 12
###begin title 13
GCase protein levels in diltiazem-treated cultured fibroblasts.
###end title 13
###begin p 14
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
###xml 282 288 <span type="species:ncbi:9986">rabbit</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
(A) Immunoblot of mouse GCase and beta-actin protein in diltiazem (12.5 microM) treated and untreated WT, 4L, 9H, C-/- and 4L;C* cell lysates. GCase protein signal levels were increased in the diltiazem-treated cells. GCase proteins in these fibroblast extracts were detected using rabbit anti-mouse GCase antibody. beta-actin was the loading control. (B) Fold changes in GCase protein signal levels in diltiazem (Dil)-treated cells relative to untreated cells. GCase protein levels were significantly increased in treated cells. Quantitation was performed using Molecular Dynamics ImageQuant 5.0 Software using the ratio of GCase/beta-actin for normalization. Each experiment was repeated in triplicate. Fold-changes (mean +/- S.E.M) of diltiazem effects on GCase for each cell line are above the columns. Student's t test, ***, p<0.001; **, p<0.01; *, p<0.05.
###end p 14
###begin title 15
Diltiazem treatment increased localization of GCase protein in lysosome.
###end title 15
###begin p 16
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
(Top panel) Compared to untreated cells, enhanced GCase signals (green) in diltiazem (25 microM) treated mouse V394L fibroblasts colocalized with LysoTracker (Red). LysoTracker (Red) fluorescence intensities were equivalent in both treated and untreated cells. (Bottom panel) Increased D409H GCase (green) expression after diltiazem (25 microM) treatment was partially localized with Lamp1 (Red), a lysosomal marker. Most of the D409H GCase was localized to the perinuclear region before treatment. Scatter plots showed colocalization of GCase in the green FITC channel with LysoTracker or Lamp1 in the red Rhodamine channel in the upper right quadrant (arrow). For lysosome markers, LysoTracker was used for V394L cells and anti-Lamp1 was used for D409H cells.
###end p 16
###begin title 17
Pearson's correlation coefficients in fibroblasts treated with diltiazem (25 microM).
###end title 17
###begin p 18
, Pearson's correlation coefficients were determined using Zeiss Axiovision colocalization software and presented as mean +/- S.E.
###end p 18
###begin p 19
Diltiazem treatment significantly increased Pearson's correlation coefficients, indicating enhanced lysosome localization of GCase. Data were analyzed by Student's t test.
###end p 19
###begin p 20
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Nunia1">[16]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Luszczki1">[17]</xref>
###xml 679 685 679 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g004">Fig. 4</xref>
###xml 749 755 749 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g004">Fig. 4</xref>
###xml 924 930 924 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g004">Fig. 4</xref>
###xml 1021 1028 1009 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g004">Fig. 4B</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 869 873 <span type="species:ncbi:10090">mice</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1135 1139 <span type="species:ncbi:10090">mice</span>
To evaluate the in vivo effects of LTCC blockers on mutant GCase activity, diltiazem was administered to the mice since its effects in fibroblast cultures were more significant than those with verapamil. The doses were determined from the Pediatric Lexi-Drugs reference and from published studies on rodents [16], [17]. WT and GCase point-mutated (V394L and D409H homozygotes) mice at 4 wks were given diltiazem (10 mg/kg/d) in drinking water for 4 wks. GCase activities in the brain, lung, spleen, and liver were analyzed. The harvested tissues from the diltiazem-treated D409H mice showed a 1.2-fold increase in GCase activity in the liver relative to those in untreated mice (Fig. 4). V394L liver GCase activity decreased by 38% after treatment (Fig. 4). No significant change in GCase activity was detected in the brain, lung, and spleen of treated D409H and V394L mice or in any tissues from similarly treated WT mice (Fig. 4). GCase protein levels in livers from treated WT mice increased by approximately1.2-fold (Fig. 4B). In liver, variable increases (<1.2-fold) in the V394L and D409H GCase proteins were detected in treated mice (data not shown).
###end p 20
###begin title 21
###xml 48 52 <span type="species:ncbi:10090">mice</span>
GCase protein and activity in diltiazem-treated mice:
###end title 21
###begin p 22
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
(A) The 4 wk old mice were administered diltiazem in drinking water (10mg/kg/day) for 4 wks. D409H livers had approximately1.2-fold increases of GCase activity. GCase activity in V394L liver decreased 38% after treatment. No significant changes in GCase activity were detected in WT, D409H and V394L brain, spleen, and lung. (B) Immunoblot analyses of GCase protein levels in WT liver. Diltiazem (10 mg/kg/d) increased GCase protein by approximately1.2 fold in WT liver. Fold change is presented as the ratio relative to untreated samples. Quantitation of blots was performed using Molecular Dynamics ImageQuant 5.0 Software and using the ratio of GCase/beta-actin for normalization. Each experiment was repeated in triplicate. n = 3 to 7 mice. Student's t test, **, p<0.01; *, p<0.05.
###end p 22
###begin p 23
###xml 624 628 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Flynn1">[18]</xref>
###xml 1018 1024 994 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007320-g005">Fig. 5</xref>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 834 839 <span type="species:ncbi:10090">mouse</span>
###xml 987 991 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
To ensure drug delivery and effective doses, additional two studies were conducted for 4 wks. Diltiazem (28 mg/kg/day) via drinking water was administered to D409H mice, and a higher dose of diltiazem (44 mg/kg/d) was given to V394L mice. The GCase activity in the brains and livers of these treated mice were not significantly altered compared to their untreated genotype-matched controls (data not shown). Additional D409H mice were given diltiazem by intraperitoneal injections with 50, 100 or 200 mg/kg/d for 7 days. These doses are approximately5-22 times greater than those (6-9 mg/kg/d) used in hypertensive patients [18]. After each injection the mice had very slow movements and major decreases in cage activity for several hours - an indication of toxicity. Full recovery to normal activity was evident by the next day. One mouse in the 200 mg/kg/d group died after the second injection. Small increases of brain GCase activities (approximately1.2-fold) were detected in D409H mice receiving 50-200 mg/kg/d (Fig. 5). The effects on liver D409H GCase activities were minor. GCase activities were not altered in the lung and spleen of D409H mice (data not shown).
###end p 23
###begin title 24
###xml 18 22 <span type="species:ncbi:10090">mice</span>
GCase activity in mice receiving diltiazem by intraperitoneal injection:
###end title 24
###begin p 25
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
The 9H mice were given diltiazem by intraperitoneal injections at 50, 100 or 200 mg/kg/d for 7 days. GCase activity increased by approximately1.2 fold in the brain of D409H mice at each of the three doses, i.e., the response was not dose dependent. No significant alterations of GCase activity were detected in the liver. Each experiment was repeated in triplicate. Untreated WT samples were also used as controls, n = 3 mice. Student's t test, *, p<0.05.
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Flynn1">[18]</xref>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Rigat1">[14]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Rigat1">[14]</xref>
###xml 1179 1183 1179 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Sun1">[19]</xref>
###xml 1328 1332 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Zhang1">[20]</xref>
###xml 577 582 <span type="species:ncbi:9606">human</span>
###xml 626 631 <span type="species:ncbi:10090">mouse</span>
The LTCC blockers diltiazem and verapamil are approved by the FDA to treat hypertension and cardiac arrhythmias. They bind to LTCCs on the cell membrane and block calcium influx that could alter homeostasis in the ER [12], [18]. LTCC blockers enhanced mutant GCase activity and lysosomal targeting in fibroblasts from individuals with Gaucher disease and were suggested to have potential therapeutic use [12], [14]. The mechanism of how LTCC blockers alter GCase is not clear, but they appear to disrupt the unfolded protein response in these cells. Similar to the findings on human cultured fibroblasts [12], [14], analogous mouse cells carrying GCase point mutations showed increases in GCase protein and activity, and lysosome localization when cultured in the presence of diltiazem or varapamil. Diltiazem exhibited greater enhancements of the WT or mutant GCases than verapamil. However, neither diltiazem nor verapamil recovered GCase activity to heterozygote levels in the mutant cells. Curiously, the WT GCase activity in saposin C-deficient cells was increased by LTCC blockers. As one of its functions saposin C protects GCase from protease degradation in the lysosome [19]. Also, diltiazem inhibits the activity of the lysosomal nicotinic acid adenine dinucleotide phosphate (NADDP)-sensitive calcium release channel [20]. These findings imply additional effects of LTCC blockers at the lysosomal level that alter GCase stability directly in that organelle.
###end p 27
###begin p 28
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Flynn1">[18]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Naito1">[21]</xref>
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Nunia1">[16]</xref>
###xml 495 499 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Westermann1">[22]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Biala1">[23]</xref>
###xml 477 482 <span type="species:ncbi:10090">mouse</span>
###xml 647 653 <span type="species:ncbi:9606">humans</span>
The bioavailability and drug metabolism of diltiazem have been studied extensively [18] and, importantly, diltiazem penetrates through the blood brain barrier [21]. In animal models, intraperitoneal, intravenous injections or oral administration of diltiazem in doses ranging from 10 to 200 mg/kg/d were effective in suppressing nicotine-induced place conditioning, protection of irradiation, and prevention of diastolic heart failure in a familial hypertrophic cardiomyopathy mouse model [16], [22], [23]. The doses of diltiazem used here (10-200 mg/kg/d) were greater than those used in a clinical setting to treat hypertension (6-9 mg/kg/d) in humans. At such high doses, the D409H mutant GCase activity was only incrementally enhanced in vivo.
###end p 28
###begin p 29
###xml 155 158 155 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Weinreb1">[9]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Lieberman1">[13]</xref>
###xml 704 708 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Mu1">[12]</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Sawkar1">[24]</xref>
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Steet1">[25]</xref>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Kornhaber1">[26]</xref>
###xml 733 740 733 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1391 1398 1391 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1729 1736 1717 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 1146 1151 <span type="species:ncbi:10090">mouse</span>
###xml 1385 1389 <span type="species:ncbi:10090">mice</span>
###xml 1480 1484 <span type="species:ncbi:10090">mice</span>
###xml 1581 1585 <span type="species:ncbi:10090">mice</span>
The success of enzyme therapy (ET) for Gaucher disease has shifted the phenotype of the nonneuronopathic variant, type 1, toward normalcy in many patients [9]. However, the inability of macromolecules, like enzymes, to traverse the blood brain barrier (BBB) in sufficient amounts so to alter the CNS lysosomal storage has led to the search for alternative methods of treatment. Several small molecules have been the focus of interest, because they penetrate the BBB, modulate protein folding, and/or trafficking of endogenous mutant enzymes, e.g., GCase, to the lysosomes [12], [13]. The majority of these "chaperones" were evaluated in cultured cells, particularly fibroblasts from affected individuals [12], [24], [25], [26]. Such ex vivo studies provided data as proof-of-principle and suggest promise for their use as treatments for the neuronopathic variants of Gaucher disease. The therapeutic effects of these "chaperones" have not been tested in animal models with residual mutant GCase activity/protein to provide a physiological foundation for their potential clinical significance. Here, cells and tissues from our point-mutated GCase mouse models of GCase defective function were tested using LTCC blockers as potential therapeutic drugs. As shown in this study, diltiazem enhanced the activity and lysosomal trafficking of GCase in cultured fibroblasts from point mutated mice. In vivo, diltiazem had little if any effect on GCase activity or protein in WT and V394L mice. D409H fibroblasts had 1.8-fold enhancement of GCase activity by diltiazem. In D409H homozygous mice, the mutant GCase activity increase (approximately1.2-fold) was not dose-dependent. This may be due to diltiazem having reached maximal effect in vivo at the lowest dose.
###end p 29
###begin p 30
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Eder1">[27]</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Liu1">[28]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Sinclair1">[29]</xref>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Enquist1">[30]</xref>
###xml 1074 1077 1074 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Grabowski1">[2]</xref>
###xml 588 592 <span type="species:ncbi:10090">Mice</span>
###xml 614 619 <span type="species:ncbi:9606">human</span>
###xml 844 848 <span type="species:ncbi:10090">mice</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
Thus, there is a discrepancy between the in vivo and ex vivo effects of diltiazem on GCase. The factors that contribute to these differential drug effects may include the effect of LTCC blockers on dividing (fibroblasts) versus non-dividing cells (neuron), the penetration efficiency of the drug into the ER (or lysosomes) in organs versus the cultured cells, and the distribution of LTCCs in different cell types and organs. The variation in expression of LTCCs on the membranes of microglial cells and macrophages is also impacted by various cellular states and microenvironments [27]. Mice with the most common human Gaucher disease mutations, N370S and L444P, have early lethality [8], [28], and thus, are not available for these studies. In addition, the alternative tissue specific knock-out models, the macrophage or neuronal GCase null mice [29], [30], would not be useful for these studies since residual GCase activity is required for LTCC blockers to have any effect. However, the D409H mutation is relatively common in the neuronopathic Gaucher disease variants [2], and, although rare, V394L has very similar kinetic and cellular properties, including response to LTCC blockers, as N370S. Thus, the use of LTCC blockers up to toxic doses in mice with such GCase mutations appears ineffective in significantly altering the mutant GCase activity or protein, suggesting that the LTCC blockers tested here would have no place in the treatment of individuals with Gaucher disease.
###end p 30
###begin title 31
Materials and Methods
###end title 31
###begin title 32
Ethics Statement
###end title 32
###begin p 33
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 126 134 <span type="species:ncbi:9606">Children</span>
The mice were maintained in microisolators in accordance with institutional guidelines under IACUC approval at the Cincinnati Children's Hospital Medical Center.
###end p 33
###begin title 34
Cell culture and drug treatment
###end title 34
###begin p 35
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 384 390 <span type="species:ncbi:9913">bovine</span>
The mouse fibroblasts were derived from WT and point-mutated GCase mice including homozygotes for V394L, D409H, and N370S, the compound heterozygous D409V/N370S, homozygous selective saposin C deficiency (C-/-), and combined homozygotes for V394L and saposin C deficiency (4L;C*). The fibroblasts were established from the skin of one-day-old pups and cultured in DMEM with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. The cells were seeded at 35% confluence and incubated with diltiazem hydrochloride (Bedford Laboratories, Bedford, OH) or verapamil (Hospira, INC., Lake Forest, IL) at series concentrations for 5 days. The cells were harvested for analysis.
###end p 35
###begin title 36
GCase activity assay
###end title 36
###begin p 37
###xml 382 385 379 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
The tissues were collected from saline-perfused mice. Fibroblasts and tissues were homogenized in 0.25% Triton X-100 and 0.25% sodium taurocholate in citric buffer, pH 5.6. GCase activities in the tissue and cell lysates were determined as described with 4-methylumbelliferryl beta-D-glucopyranoside (4 MU-Glc, 4 mM) as substrate in 0.25% sodium taurocholate and 0.25% Triton X-100 [8]. Assay mixtures were preincubated in the presence and absence of the conduritol B epoxide (CBE, 1 mM), a specific irreversible inhibitor of GCase, for 30 min at 37degreesC. The substrate (4 MU-Glc) was added to the mixture, and incubated for 30 min at 37degreesC. Protein concentration was determined using the BCA protein assay reagent.
###end p 37
###begin title 38
Immunoblot Analyses
###end title 38
###begin p 39
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Sun2">[31]</xref>
###xml 232 234 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 265 271 <span type="species:ncbi:9986">Rabbit</span>
###xml 277 282 <span type="species:ncbi:10090">mouse</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
###xml 344 349 <span type="species:ncbi:10090">mouse</span>
The tissue and cell lysates were prepared as described [31]. The cell (50 microg) and tissue (200 microg) lysates were resolved on Invitrogen NuPAGE 4-12% Bis-Tris gel with NuPAGE MED SDS running buffer and electro-blotted on HybondTM-ECL nitrocellulose membranes. Rabbit anti-mouse GCase (1/1000 in 3% BSA) was used to detect mouse GCase, and mouse anti-beta-actin monoclonal antibody (1/10,000) was used to detect beta-actin. The signals were developed using an ECL reagent (Amersham Biosciences, Piscataway, NJ) according to the manufacturer's instructions.
###end p 39
###begin title 40
Fibroblast Colocalization Studies
###end title 40
###begin p 41
###xml 341 342 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 498 504 <span type="species:ncbi:9986">rabbit</span>
###xml 510 515 <span type="species:ncbi:10090">mouse</span>
###xml 618 624 <span type="species:ncbi:9986">rabbit</span>
###xml 630 635 <span type="species:ncbi:10090">mouse</span>
###xml 646 649 <span type="species:ncbi:10116">rat</span>
###xml 655 660 <span type="species:ncbi:10090">mouse</span>
###xml 776 780 <span type="species:ncbi:9925">goat</span>
###xml 786 792 <span type="species:ncbi:9986">rabbit</span>
###xml 809 813 <span type="species:ncbi:9925">goat</span>
###xml 819 822 <span type="species:ncbi:10116">rat</span>
Fibroblasts were treated with diltiazem at 25 microM for 5 days. LysoTracker Red (Molecular probe, L-7528) was applied to the V394L, WT, C-/-, and 4L;C* cells at 100 nM for 30 min at 37degreesC. The cells were rinsed with 1x PBS and fixed in 3% paraformaldhyde for 40 min at room temperature (RT). The fixed cells were quenched with 50 mM NH4Cl, rinsed with 1x PBS, and then treated with 0.5% saponin (Sigma, S-7900) and 1% BSA in 1 x PBS for 5 min at RT three times. The cells were incubated with rabbit anti-mouse GCase IgG (1/100) in 0.5% saponin-PBS, 1% BSA overnight at 4degreesC. D409H cells were incubated with rabbit anti-mouse GCase and rat anti-mouse Lamp1 (DRI, CD107a-D4B) (1/200) as a lysosome marker. The cells were washed with 0.5% saponin-PBS and labeled with goat anti-rabbit FITC (1/100) or goat anti-rat Texas red (1/100) for 1 hour at RT. Following a 0.5% saponin-PBS wash, the cells were mounted with mounting medium containing DAPI (Vector Laboratory). Fluorescence signals were visualized by Zeiss Axiovert 200 M microscopy equipped with an Apotome. Pearson's correlation coefficients were determined for individual cells using Zeiss Axiovision colocalization software. The data was analyzed by Student's t-test.
###end p 41
###begin title 42
Animal care and drug administration
###end title 42
###begin p 43
###xml 84 87 84 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007320-Xu1">[8]</xref>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 462 467 <span type="species:ncbi:10090">mouse</span>
###xml 822 826 <span type="species:ncbi:10090">mice</span>
The GCase point-mutated V394L and D409H homozygous mice were generated as described [8]. The strain background of V394L and D409H mice was C57BL/6J/129SvEV. WT mice are in FVB background. Drug administration was started in the mice at 4 wks of age. The first cohorts (homozygotes for V394L and D409H, and WT) were given diltiazem via drinking water at 10 mg/kg/d for 4 weeks. The dose in drinking water was determined using average daily water intake (5 ml) and mouse weight. The second cohort (D409H) was administered diltiazem by intraperitoneal injection at three doses: 50, 100, or 200mg/kg/d for 7 days. The third cohort, included D409H and V394L homozygotes, was given diltiazem in drinking water for 4 wks at 28 mg/kg/d for D409H homozygotes and 44 mg/kg/d for V394L homozygotes. The cage activities of the treated mice were monitored during the study.
###end p 43
###begin p 44
The authors thank Venette Inskeep, Rebecca Coyle, Matt Zamzow, and Lori Stanton for their technical assistance and Brandy Morris for her clerical expertise.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
Gaucher Disease.
###end article-title 46
###begin article-title 47
Gaucher disease: Phenotypic and genetic variation. Chapter 146.1.
###end article-title 47
###begin article-title 48
###xml 53 58 <span type="species:ncbi:9606">human</span>
Intracellular transport of acid alpha-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system.
###end article-title 48
###begin article-title 49
###xml 71 79 <span type="species:ncbi:9606">patients</span>
The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.
###end article-title 49
###begin article-title 50
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Prevalent and rare mutations among Gaucher patients.
###end article-title 50
###begin article-title 51
The glucocerebrosidase D409H mutation in Gaucher disease.
###end article-title 51
###begin article-title 52
Gaucher disease: molecular heterogeneity and phenotype-genotype correlations.
###end article-title 52
###begin article-title 53
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.
###end article-title 53
###begin article-title 54
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
###end article-title 54
###begin article-title 55
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
###end article-title 55
###begin article-title 56
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
###end article-title 56
###begin article-title 57
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.
###end article-title 57
###begin article-title 58
Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
###end article-title 58
###begin article-title 59
###xml 96 103 <span type="species:ncbi:9606">patient</span>
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
###end article-title 59
###begin article-title 60
Quantitative colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena.
###end article-title 60
###begin article-title 61
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Protective effect of diltiazem (a calcium channel blocker) against cadmium-induced toxicity in mice.
###end article-title 61
###begin article-title 62
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock-induced seizure model.
###end article-title 62
###begin article-title 63
Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension.
###end article-title 63
###begin article-title 64
Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation.
###end article-title 64
###begin article-title 65
###xml 150 154 <span type="species:ncbi:10116">rats</span>
Reconstitution and characterization of a nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca2+ release channel from liver lysosomes of rats.
###end article-title 65
###begin article-title 66
###xml 114 121 <span type="species:ncbi:9986">rabbits</span>
Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits.
###end article-title 66
###begin article-title 67
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy.
###end article-title 67
###begin article-title 68
Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents.
###end article-title 68
###begin article-title 69
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.
###end article-title 69
###begin article-title 70
The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.
###end article-title 70
###begin article-title 71
Isofagomine induced stabilization of glucocerebrosidase.
###end article-title 71
###begin article-title 72
Ion channels in microglia (brain macrophages).
###end article-title 72
###begin article-title 73
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure.
###end article-title 73
###begin article-title 74
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
###end article-title 74
###begin article-title 75
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine models of acute neuronopathic Gaucher disease.
###end article-title 75
###begin article-title 76
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking.
###end article-title 76
###begin p 77
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 77
###begin p 78
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NIH grants to G.A.G (R01 NS/DK36681 and DK36729). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 78

